ADVENTRX Pharmaceuticals, Inc. (NYSE Amex:ANX) recently announced that Santosh J. Vetticaden, M.D., Ph.D., will join the Company as Chief Medical Officer and Senior Vice President.

A biopharmaceutical company, ADVENTRX Pharmaceuticals, Inc. is focused on developing proprietary product candidates.

Dejour Energy Inc. (NYSE Amex:DEJ) recently announced the release of its financial results for the 2nd quarter period ended June 30, 2012. For the 3 months ended June 30, 2012, the Company recorded $1,771,000 in oil and natural gas sales as compared to $1,816,000 in oil and natural gas sales for the 3 months ended June 30, 2011.

Dejour Energy Inc. is engaged in exploring, acquiring, and developing energy projects focusing on oil and gas exploration in the United States and Canada.

Hemispherx Biopharma, Inc. (NYSE Amex:HEB) filed on July 31, 2012 with the U.S. Food and Drug Administration its finished response to the FDA’s November 25, 2009 Complete Response Letter in support of Ampligen’s New Drug Application for Chronic Fatigue Syndrome. On August 10, 2012, the FDA gave acknowledgement in writing receipt of the Company’s August 1, 2012, response.

Hemispherx Biopharma, Inc. is engaged in the clinical development and manufacturing of new drug entities for treatment of seriously debilitating disorders.

PharmAthene, Inc. (NYSE Amex:PIP) recently announced it has received notification from the U.S. Food and Drug Administration that the SparVax rPA anthrax vaccine program has been placed on clinical hold.

A biodefense company, PharmAthene, Inc. is engaged in the commercialization and development of medical countermeasures against biological and chemical threats in the United States.

******************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. galaxystocks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer ( http://galaxystocks.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold galaxystocks.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE) advertises for a particular client, Crown Equity Holdings Inc. (CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE), if paid in stock, can and may sell those securities during the advertising period.

Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Entire Disclaimer Here